Here at Cambridge Molecular Diagnostics Ltd., as leaders in transforming the sensitivity, viability and profitability of lateral flow testing, we’ve appointed Prof. Denis Kinane, an experienced biotech entrepreneur, academic, investor and executive, as Non-Executive Chair of the Board. Prof. Kinane will bring his extensive experience in diagnostic products to the company, combined with his track record of leading innovative scientific companies globally.
Prof. Kinane joins the company to help build on the tremendous technological progress made over the last four years. During this time, the company has launched its unique patented signal amplification technology and its novel DNA detection technology. Together, these innovations enable the detection of low levels of specific DNA sequences without the need for additional sample processing or expensive DNA amplification methods. Denis will primarily work with the SwiftDx team in taking products through regulatory certification and delivering the products to market. “The combination of Denis’s scientific understanding of our technology and his proven experience of bringing diagnostic tests to market is a vital piece of the next stage of SwiftDx’s growth”, said Ben Shaw, CEO and Co-Founder of SwiftDx.
Prof. Denis F. Kinane BDS FDSRCS PhD FDSRCPS has worked in academia for 35 years, where he has been Professor in Periodontics, Pathology and Otolaryngology at the Perelman School of Medicine (University of Pennsylvania) and Dean at University of Pennsylvania Dental School, where he served for nine years. Prior to that, he spent seven years as Research Dean at University of Louisville, and 14 years in the same post at Glasgow University. Currently, he holds a professorship at the University of Bern, Switzerland.
Prof. Kinane is Director of two large US and Chinese Health Companies and Scientific Director, CMO and founder of several smaller international companies. Most recently, he was founding scientist at Cignpost Diagnostics Ltd. (www.cignpostdiagnostics.com), a leading provider of diagnostic services to elite sport, corporate, movie and airport industries.
“I am both delighted and excited to be joining SwiftDx as Non-Executive Chairman at this pivotal time for the company. My experience in taking diagnostic products to market is a perfect fit for the SwiftDx management team, as the company’s first products are prepared for market release”, said Prof. Kinane.
For further information, contact Dr Ben Shaw, CEO, at ben.shaw@swiftdx.co.uk.
Abbreviations: BDS: Bachelor of Dental Surgery; CEO, Chief Executive Officer; CMO: Chief Medical Officer; DNA: deoxyribonucleic acid; FDSRCS: Fellowship in Dental Surgery of the Royal College of Surgeons of England; FDSRCPS: Fellowship in Dental Surgery of the Royal College of Physicians and Surgeons of Glasgow; Ltd.: limited; PhD: Doctor of Philosophy; US: United States.